Curative chest re‑irradiation for thoracic cancers
CUratively Intended Thoracic REirradiation: An Observational Study of High-dose Reirradiation of Thoracic Tumours: A Multicentre Prospective Registration Protocol
This project will try a standardized high‑dose re‑radiation approach for adults with recurrent or new thoracic cancers who previously received chest radiotherapy to see how well it controls disease and what toxicities occur.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 500 (estimated) |
| Sex | All |
| Sponsor | University of Aarhus Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Aarhus, Jutland) |
| Trial ID | NCT06950073 on ClinicalTrials.gov |
What this trial studies
This is a Danish multicenter prospective cohort collecting detailed radiotherapy dose data, toxicity events, loco‑regional control, and overall survival for patients receiving curative‑intent thoracic reirradiation. The protocol requires available digital prior treatment plans (DICOM) and uses predefined dose‑accumulation methods and provisional organ‑at‑risk constraints to harmonize treatment across sites. Data will feed into national infrastructure and decision tools to support shared decision‑making and referral pathways. Four substudies will address implementation, dose constraints, outcomes, and safety to create a uniform clinical framework for reirradiation.
Who should consider this trial
Good fit: Adults (≥18) with a recurrent or new thoracic malignancy who previously received thoracic radiotherapy, have ECOG 0–2, estimated life expectancy ≥6 months, suitable lung function, and available prior digital radiotherapy plans (DICOM).
Not a fit: Patients with very poor performance status, life expectancy under six months, diffuse metastatic disease not amenable to local control, or without accessible prior digital radiotherapy plans are unlikely to benefit from this approach.
Why it matters
Potential benefit: If successful, the project could make reirradiation safer and more widely available by defining dose‑limits and predicting toxicity, improving local control and survival for selected patients.
How similar studies have performed: Previous retrospective and small prospective series of thoracic reirradiation have shown variable survival and relatively high severe toxicity, so the approach is promising but not yet well proven in large standardized cohorts.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Radiotherapy of thoracic lesion(s) (loco-regional lung cancer recurrence, new primary lung cancer, or solitary oligo metastasis) with the aim of long-term local control. * Reirradiation type 1 or type 2, i.e. previous radiotherapy to the thorax as per ESTRO-EORTC consensus definition of reirradiation \[Andratschke 2022\]. For the sake of this study, multiple treatments to the lungs will be classified as type 2 reirradiation. * Verification of malignancy based on biopsy. If no biopsy is available, the decision of reirradiation should be agreed upon in a multidisciplinary conference. * Available digital dose plan(s) from former radiotherapy course(s) (DICOM files) - note that multiple re-treatments are allowed. * Adequate lung function to tolerate treatment, at the discretion of the treating physician. * Ability to complete a radiotherapy course with the aim of local control. * ECOG Performance status 0-2. * Estimated life expectancy ≥ 6 months * Age ≥18 years * Signed informed consent Exclusion Criteria: * Uncontrolled other malignancy. * The primary and the reirradiation treatment may not be quasi-simultaneous (i.e. the two treatments should be planned independently) * Pregnancy * Radiotherapy to a minimum CTV mean dose of 45 Gy for SCLC and 50 Gy for NSCLC and oligometastatic lesions. Treatment schedule according to local protocols and treating physician preference.
Where this trial is running
Aarhus, Jutland
- Aarhus University Hospital — Aarhus, Jutland, Denmark (Recruiting)
Study contacts
- Study coordinator: Stine O Fredslund, MD, PhD
- Email: stin.fred@auh.rm.dk
- Phone: +45 28713076
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.